{"DataElement":{"publicId":"5584484","version":"1","preferredName":"Person Progressive Disease Response Assessment in Neuro-Oncology Criteria Therapeutic Procedure Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to cancer that is increasing in scope or severity by RANO criteria and the administration of therapeutic agents that produce an effect intended to alter or stop a pathologic process as outlined in the protocol.","longName":"PRDZ_RANO_TX_IND","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"5584461","version":"1","preferredName":"Person Progressive Disease Response Assessment in Neuro-Oncology Criteria Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._Cancer that is increasing in scope or severity._An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM)._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2236731v1.0:5584459v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5584459","version":"1","preferredName":"Progressive Disease Response Assessment in Neuro-Oncology Criteria Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"Cancer that is increasing in scope or severity.:An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C35571:C114879:C49236:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Response Assessment in Neuro-Oncology Criteria","conceptCode":"C114879","definition":"An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"429F9451-D89D-6969-E053-F662850AFED7","latestVersionIndicator":"Yes","beginDate":"2016-12-01","endDate":null,"createdBy":"LOWMAND","dateCreated":"2016-12-01","modifiedBy":"ONEDATA","dateModified":"2016-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"429F9451-D8AE-6969-E053-F662850AFED7","latestVersionIndicator":"Yes","beginDate":"2016-12-01","endDate":null,"createdBy":"LOWMAND","dateCreated":"2016-12-01","modifiedBy":"LOWMAND","dateModified":"2017-04-24","changeDescription":"12/1/16 dl, EAF151","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[{"name":"PRDZ_RANO_TX_IND","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Does the patient have progres","type":"Preferred Question Text","description":"Does the patient have progression of disease as assessed by the local site using RANO criteria, with the plan to give whole-dose bevacizumab therapeutically, either as a single therapy or in conjunction with other chemotherapeutic regimen?","url":null,"context":"ECOG-ACRIN"},{"name":"ACRIN - 1","type":"Alternate Question Text","description":"Does the patient have progression of disease as assessed by the local site using RANO criteria, with the plan to administer bevacizumab, either as a single therapy or in conjunction with other chemotherapeutic regimen?","url":null,"context":"ECOG-ACRIN"},{"name":"ACRIN - 2","type":"Alternate Question Text","description":"Does the patient have progression of disease as assessed by the local site using RANO criteria, with the plan to administer bevacizumab, either as single therapy or in conjunction with other chemotherapy regimens, in order to treat tumor progression/recurrence per the treating physician?","url":null,"context":"ECOG-ACRIN"},{"name":"ACRIN - 3","type":"Alternate Question Text","description":"Does the patient have progression of disease as assessed by the local site using RANO criteria, with the plan to administer bevacizumab, either as single therapy or in conjunction with other chemotherapeutic or immunotherapy regimens, in order to treat tumor progression/recurrence per the treating physician?","url":null,"context":"ECOG-ACRIN"},{"name":"ACRIN - 4","type":"Alternate Question Text","description":"Does the patient have progression of disease as assessed by the local site using RANO criteria, with the plan to administer bevacizumab or its biosimilars, either as single therapy or in conjunction with other chemotherapeutic or immunotherapy regimens, in order to treat tumor progression/recurrence per the treating physician?","url":null,"context":"ECOG-ACRIN"}],"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42A01435-14C0-3920-E053-F662850AC0D5","latestVersionIndicator":"Yes","beginDate":"2016-12-01","endDate":null,"createdBy":"LOWMAND","dateCreated":"2016-12-01","modifiedBy":"TAYLORT","dateModified":"2021-03-12","changeDescription":"12/2/16 tt, edit to draft new. 12/1/16 dl, EAF151.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}